
[EPISODE 20] Dr. David Johnson Talks Frosted Flakes, Small Molecules, and Pharmacokinetics!
On this episode of Molecular Moments, Dr. Jim McNally chats with DMPK Senior Director Dr. David Johnson, Ph.D., from BioAgilytix
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
34,000 Square Feet
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
78,685 Square Feet
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
26,453 Square Feet
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
2,777 Square Meters
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Dr. Jim McNally chats with DMPK Senior Director Dr. David Johnson, Ph.D., from BioAgilytix
Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
Summary In an article published by Pharmaceutical Technology Europe, BioAgilytix BioAgilytix supplies its assay expertise to describe the appropriate analytical
Summary In an Expert Opinion article published by Contract Pharma, PD Dr. Arno Kromminga of BioAgilytix discusses testing challenges and
Durham, NC, July 21, 2022 – BioAgilytix Labs, LLC (BioAgilytix) has secured a valuable seal of approval for the safety of
Durham, NC, June 30, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical
Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
ADCC Antibody dependent cellular cytotoxicity (ADCC) is a mechanism in host immune defense where antibodies bind to an antigen on
Gene editing isn’t a new concept and has been around for decades. In its infancy, gene editing was time-consuming, inaccurate
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
34,000 Square Feet
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
78,685 Square Feet
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
26,453 Square Feet
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
2,777 Square Meters
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Dr. Jim McNally chats with DMPK Senior Director Dr. David Johnson, Ph.D., from BioAgilytix
Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
Summary In an article published by Pharmaceutical Technology Europe, BioAgilytix BioAgilytix supplies its assay expertise to describe the appropriate analytical
Summary In an Expert Opinion article published by Contract Pharma, PD Dr. Arno Kromminga of BioAgilytix discusses testing challenges and
Durham, NC, July 21, 2022 – BioAgilytix Labs, LLC (BioAgilytix) has secured a valuable seal of approval for the safety of
Durham, NC, June 30, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical
Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
ADCC Antibody dependent cellular cytotoxicity (ADCC) is a mechanism in host immune defense where antibodies bind to an antigen on
Gene editing isn’t a new concept and has been around for decades. In its infancy, gene editing was time-consuming, inaccurate
As one of the largest bioanalytical LC/MS service providers in the U.S., we specialize in developing and validating robust bioanalytical methods for the quantification of API and metabolites in various biological matrices, using LC/MS (HPLC, UPLC, 2-D chromatography), HPLC/UV, and HPLC/Fluorescence techniques. We provide industry-leading small molecule bioanalysis for drug development.
We provide the following services for small molecule bioanalysis:
We provide discovery bioanalysis (non-GLP), regulated bioanalysis, and high-throughput bioanalysis for small molecules to support the following therapeutic development studies: develop, validate, and perform laboratory developed tests (LDTs) and FDA-cleared assays.
We provide discovery bioanalysis (non-GLP), regulated bioanalysis, and high-throughput bioanalysis for small molecules to support the following therapeutic development studies: develop, validate, and perform laboratory developed tests (LDTs) and FDA-cleared assays.
BioAgilytix has developed more than 2,400 proprietary and non-proprietary methods, including many validated and ready-to-validate non-proprietary assays for small molecule bioanalysis.
BioAgilytix occupies 34,000 square feet of office and laboratory space in San Diego, California. Our cutting-edge instrumentation and facilities allow us to increase sample throughput and perform complex separations. Our LC/MS systems and diverse sample preparation technologies allow us to efficiently and accurately analyze large quantities of samples for clients who need high-throughput bioanalysis of clinical study samples.
Learn how the development of a non-traditional internal standard by derivatization allowed our client to maintain their rigorous timeline, without resorting to an expensive synthetic effort.
BioAgilytix assembles and distributes protocol-specific specimen collection kits to simplify and streamline the PK collection process for single and multi-site clinical trials. Kits are tailored to your specific sampling needs and can be shipped worldwide. The specimen samples collected can be returned to the testing laboratory of your choice for small molecule bioanalysis.
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
37 Kent St, Woolloongabba
Queensland, 4102, Australia
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 617-456-0700
37 Kent St,Woolloongabba
Queensland, 4102, Australia
1320 Soldiers Field Road
Boston, MA, 02135
1320 Soldiers Field Road
Boston, MA, 02135
617-456-0700
Fax 617-456-0701
Lademannbogen 10
22339 Hamburg Germany
+49 405267790
85 Commercial Road, Melbourne
Victoria, 3004, Australia
03 9282 2184
Lademannbogen 10
22339 Hamburg Germany
85 Commercial Road, Melbourne
Victoria, 3004, Australia
Copyright © 2022 BioAgilytix Labs.
All rights reserved.